Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC : The role of systemic progression control
© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd..
BACKGROUND: Approximately 3%-5% of lung adenocarcinoma is driven by anaplastic lymphoma kinase (ALK) fusion oncogene, whose activity can be suppressed by multiple ALK inhibitors. Crizotinib and ceritinib have demonstrated superior efficacy to platinum-based chemotherapy as front-line treatment for patients with ALK-positive advanced non-small cell lung cancer (NSCLC). However, the direct comparison between them in the front-line setting remains lacking.
METHODS: A total of 48 patients with ALK-positive, previously untreated advanced NSCLC, who received crizotinib and ceritinib as front-line treatment were retrospectively investigated. The efficacy and pattern of disease progression were analyzed.
RESULTS: Patients receiving ceritinib treatment were significantly younger than those receiving crizotinib treatment (52.0 vs. 63.0, P = 0.016). The median progression-free survival (PFS) was significantly longer with ceritinib than with crizotinib treatment (32.3 vs. 12.9 months; log-rank P = 0.020); the hazard ratio for disease progression or death, 0.27 (95% CI, 0.08-0.90; P = 0.033). An objective response was noted in all patients in the ceritinib group and in 23 patients in the crizotinib group (74.2%; 95% CI, 59.0 to 88.5). The rate of systemic progression was significantly lower over time with ceritinib treatment compared to crizotinib treatment (cause-specific hazard ratio, 0.21; 95% CI 0.06-0.73; P = 0.014). Serious adverse events were noted in one (2.9%) patient showing elevated liver function in the crizotinib group and three (23.1%) patients showing diarrhea in the ceritinib group. Dose reduction was needed in five out of 13 (38.5%) patients receiving ceritinib treatment.
CONCLUSION: Ceritinib showed higher efficacy associated with a better control of systemic progression compared to crizotinib for the front-line treatment of ALK-positive advanced NSCLCs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Thoracic cancer - 10(2019), 12 vom: 18. Dez., Seite 2274-2281 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Shih-Hao [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.08.2020 Date Revised 10.08.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1759-7714.13221 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302200819 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302200819 | ||
| 003 | DE-627 | ||
| 005 | 20231225110224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1759-7714.13221 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1007.xml |
| 035 | |a (DE-627)NLM302200819 | ||
| 035 | |a (NLM)31613427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Shih-Hao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC |b The role of systemic progression control |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.08.2020 | ||
| 500 | |a Date Revised 10.08.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND: Approximately 3%-5% of lung adenocarcinoma is driven by anaplastic lymphoma kinase (ALK) fusion oncogene, whose activity can be suppressed by multiple ALK inhibitors. Crizotinib and ceritinib have demonstrated superior efficacy to platinum-based chemotherapy as front-line treatment for patients with ALK-positive advanced non-small cell lung cancer (NSCLC). However, the direct comparison between them in the front-line setting remains lacking | ||
| 520 | |a METHODS: A total of 48 patients with ALK-positive, previously untreated advanced NSCLC, who received crizotinib and ceritinib as front-line treatment were retrospectively investigated. The efficacy and pattern of disease progression were analyzed | ||
| 520 | |a RESULTS: Patients receiving ceritinib treatment were significantly younger than those receiving crizotinib treatment (52.0 vs. 63.0, P = 0.016). The median progression-free survival (PFS) was significantly longer with ceritinib than with crizotinib treatment (32.3 vs. 12.9 months; log-rank P = 0.020); the hazard ratio for disease progression or death, 0.27 (95% CI, 0.08-0.90; P = 0.033). An objective response was noted in all patients in the ceritinib group and in 23 patients in the crizotinib group (74.2%; 95% CI, 59.0 to 88.5). The rate of systemic progression was significantly lower over time with ceritinib treatment compared to crizotinib treatment (cause-specific hazard ratio, 0.21; 95% CI 0.06-0.73; P = 0.014). Serious adverse events were noted in one (2.9%) patient showing elevated liver function in the crizotinib group and three (23.1%) patients showing diarrhea in the ceritinib group. Dose reduction was needed in five out of 13 (38.5%) patients receiving ceritinib treatment | ||
| 520 | |a CONCLUSION: Ceritinib showed higher efficacy associated with a better control of systemic progression compared to crizotinib for the front-line treatment of ALK-positive advanced NSCLCs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ALK | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a ceritinib | |
| 650 | 4 | |a crizotinib | |
| 650 | 7 | |a Oncogene Proteins, Fusion |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Sulfones |2 NLM | |
| 650 | 7 | |a Crizotinib |2 NLM | |
| 650 | 7 | |a 53AH36668S |2 NLM | |
| 650 | 7 | |a ALK protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Anaplastic Lymphoma Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ceritinib |2 NLM | |
| 650 | 7 | |a K418KG2GET |2 NLM | |
| 700 | 1 | |a Huang, Allen Chung-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chin-Chou |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Wen-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chien-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlidis, Stelios |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Ho-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Fu-Tsai |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Ping-Chih |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yi-Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Chih-Hsi Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Cheng-Ta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thoracic cancer |d 2010 |g 10(2019), 12 vom: 18. Dez., Seite 2274-2281 |w (DE-627)NLM251832414 |x 1759-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |g number:12 |g day:18 |g month:12 |g pages:2274-2281 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1759-7714.13221 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2019 |e 12 |b 18 |c 12 |h 2274-2281 | ||